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In our meta-analysis published in 2006, last updated in 2010, we described a significant
benefit for patients treated with three- drug combinations (5-FU/cisplatin/
anthracycline), as compared to 5-FU/anthracycline (HR 0.82; 95% CI 0.73–0.92), as
well as 5-FU/platinum/anthracycline-combinations versus 5-FU/P (HR 0.77; 95% CI
0.62–0.95). Are these results still valid in 2013?
1) These trials were conducted at a time when second-line chemotherapy was not
used systematically. In between, a survival benefit has been demonstrated for
second-line chemotherapy versus best supportive care in two randomized trials.
Consequently, second-line chemotherapy has become an internationally
accepted standard of care. This might decrease the relative importance of three
drug-combinations in first line therapy.
2) All trials included in this comparison used cisplatin as platinum derivate
and 5-FU as fluoropyrimidine. However, the combination of EOX has
shown to be superior to ECF, but EOX has never been compared to an
oxaliplatin-based two-drug combination. Therefore, the relative
contribution of epirubicine to the efficacy of EOX must be considered as
unclear. 3) Finally, new three-drug regimens have been developed, such as
DCF or FLOT, which might have an improved efficacy as compared to
those included in the meta-analysis.
The question is not only: is triplet superior to doublet, but how can we combine the
benefit in terms of response rate of triplet combinations with the better tolerability of
two-drug combination. Therefore, not only the development of further targeted drugs,
but as well novel treatment strategies, with for example induction and maintenance
phases, which reduce the burden of treatment as much as possible without
compromising efficacy and identify those patients who have the greatest benefit from
three- versus two-drug combinations, is highly warranted.
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